BioCentury | Jun 26, 2008
Distillery Therapeutics

This Week in Therapeutics

...Publication and contact information Cancer Prostate cancer Pituitary adenylate cyclase-activating peptide (PACAP); proopiomelanocortin (POMC); b-endorphin (BEP...
...with PACAP differentiated into BEP-producing neurons. In a rat model of prostate cancer, transplantation of BEP-producing...
...was seen in mock-treated controls. Next steps include identifying the cells and receptors needed for BEP...
BioCentury | Jun 26, 2008
Targets & Mechanisms

Prostate of Mind

...his long-standing interest in how b-endorphin ( BEP ) influences brain development, immunity and cancer. BEP...
...hypothesized that raising BEP activity might have the opposite effect and prevent tumor growth. Because BEP...
...into the hypothalamus. After confirming that the implanted BEP neurons could survive and produce extra BEP...
BioCentury | Nov 5, 2007
Product Development

Targeting obesity subgroups

Both of the obesity therapeutics Orexigen Therapeutics Inc. is developing are oral, twice-daily combinations of approved drugs that include extended-release bupropion as one of their components. But the second component of each gives the two...
BioCentury | Oct 2, 2006
Product Development

Doubling up vs. obesity

Orexigen Therapeutics Inc. believes that the joint mechanisms of action of its Contrave , which pairs depression and smoking cessation drug bupropion with alcohol dependency drug naltrexone, could overcome the "plateau" effect seen in monotherapies to...
BioCentury | Feb 26, 2001
Tools & Techniques

Untangling the Alzheimer's targets

...rats that downregulating P-glycoprotein 1 (Pgp1) with antisense oliogonucleotides reduced the brain-to-blood transport of morphine, beta-endorphin...
Items per page:
1 - 5 of 5